| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/LEU.2014.164 |
| P698 | PubMed publication ID | 24913728 |
| P50 | author | Noel Jean Milpied | Q55743774 |
| P2093 | author name string | M Labopin | |
| R F Schlenk | |||
| M Mohty | |||
| A Nagler | |||
| V Rocha | |||
| D Niederwieser | |||
| J J Cornelissen | |||
| J Versluis | |||
| D Blaise | |||
| G Socie | |||
| P2860 | cites work | Combination of the Hematopoietic Cell Transplantation Comorbidity Index and the European Group for Blood and Marrow Transplantation Score Allows a Better Stratification of High-Risk Patients Undergoing Reduced-Toxicity Allogeneic Hematopoietic Cell T | Q58041433 |
| A risk score for mortality after allogeneic hematopoietic cell transplantation | Q82892217 | ||
| Role of HCT-comorbidity index, age and disease status at transplantation in predicting survival and non-relapse mortality in patients with myelodysplasia and leukemia undergoing reduced-intensity-conditioning hemopoeitic progenitor cell transplantat | Q84533304 | ||
| A modified comorbidity index for hematopoietic cell transplantation | Q84626303 | ||
| Retrospective analysis of common scoring systems and outcome in patients older than 60 years treated with reduced-intensity conditioning regimen and alloSCT | Q85157580 | ||
| Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT | Q24685958 | ||
| The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties | Q28283156 | ||
| A new method of classifying prognostic comorbidity in longitudinal studies: development and validation | Q29547376 | ||
| Hematopoietic SCT in Europe: data and trends in 2011. | Q30616418 | ||
| Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. | Q33180040 | ||
| Assessment of the hematopoietic cell transplantation comorbidity index in non-Hodgkin lymphoma patients receiving reduced-intensity allogeneic hematopoietic stem cell transplantation | Q33743786 | ||
| A modified EBMT risk score and the hematopoietic cell transplantation-specific comorbidity index for pre-transplant risk assessment in adult acute lymphoblastic leukemia | Q33829105 | ||
| Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis | Q34555592 | ||
| Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? | Q34573884 | ||
| High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation | Q34582448 | ||
| Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences | Q34583041 | ||
| Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials | Q34608688 | ||
| Acute myeloid leukemia in the real world: why population-based registries are needed | Q35980291 | ||
| How I assess comorbidities before hematopoietic cell transplantation | Q36761518 | ||
| The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach | Q38040708 | ||
| A competing risks analysis should report results on all cause-specific hazards and cumulative incidence functions. | Q38082220 | ||
| Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks | Q39351852 | ||
| The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation. | Q40005125 | ||
| Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. | Q40407990 | ||
| Internal and external validation of predictive models: a simulation study of bias and precision in small samples | Q40556623 | ||
| CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT. | Q42269523 | ||
| Regression modelling strategies for improved prognostic prediction | Q44912226 | ||
| CMV-antigenemia after allogeneic bone marrow transplantation: correlation of CMV-antigen positive cell numbers with transplant-related mortality | Q44967238 | ||
| Validation of the EBMT risk score in chronic myeloid leukemia in Brazil and allogeneic transplant outcome | Q45264801 | ||
| Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis | Q47589093 | ||
| Regression modeling of competing crude failure probabilities | Q47671166 | ||
| Comparison of lung function after myeloablative and 2 Gy of total body irradiation-based regimens for hematopoietic stem cell transplantation | Q47820097 | ||
| Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. | Q50859540 | ||
| Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of NRM and OS in a population of patients underg | Q53359353 | ||
| Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. | Q53532028 | ||
| A Proportional Hazards Model for the Subdistribution of a Competing Risk | Q56885139 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 51-57 | |
| P577 | publication date | 2014-05-20 | |
| P1433 | published in | Leukemia | Q6534498 |
| P1476 | title | Prediction of non-relapse mortality in recipients of reduced intensity conditioning allogeneic stem cell transplantation with AML in first complete remission. | |
| P478 | volume | 29 |
| Q47432401 | Acute myeloid leukaemia. |
| Q64109318 | Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study |
| Q37270993 | Allogeneic hematopoietic cell transplantation in patients ⩾70 years: which patients may benefit? |
| Q92965514 | Allogeneic hematopoietic stem cell transplantation with fludarabine, busulfan, and thiotepa conditioning is associated with favorable outcomes in myelofibrosis |
| Q53001093 | Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 years. |
| Q39601810 | Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio |
| Q35647641 | Conditioning intensity in middle-aged patients with AML in first CR: no advantage for myeloablative regimens irrespective of the risk group-an observational analysis by the Acute Leukemia Working Party of the EBMT. |
| Q37624593 | Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel |
| Q38657161 | Effect of cytogenetic risk status on outcomes for patients with acute myeloid leukemia undergoing various types of allogeneic hematopoietic cell transplantation: an analysis of 7812 patients. |
| Q92915882 | External validation and comparison of multiple prognostic scores in allogeneic hematopoietic stem cell transplantation |
| Q35499395 | Graft-versus-host disease prophylaxis after transplantation: a network meta-analysis |
| Q40313702 | Haploidentical hematopoietic cell transplantation using in vitro T cell depleted grafts as salvage therapy in patients with disease relapse after prior allogeneic transplantation. |
| Q91785467 | Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndrome |
| Q92934940 | Individualized prediction of leukemia-free survival after autologous stem cell transplantation in acute myeloid leukemia |
| Q90590385 | Long-term results of reduced-intensity conditioning allogeneic hematopoietic cell transplantation for older patients with acute myeloid leukemia: a retrospective analysis of 10-year follow-up data |
| Q48267407 | Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1. |
| Q40190632 | Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis |
| Q98471396 | Predicting non-relapse mortality following allogeneic hematopoietic cell transplantation during first remission of acute myeloid leukemia |
| Q31052875 | Prediction of Hematopoietic Stem Cell Transplantation Related Mortality- Lessons Learned from the In-Silico Approach: A European Society for Blood and Marrow Transplantation Acute Leukemia Working Party Data Mining Study |
| Q61810932 | Predictive value of disease risk comorbidity index for overall survival after allogeneic hematopoietic transplantation |
| Q35800814 | Reduced intensity conditioning allogeneic hematopoietic cell transplantation for adult acute myeloid leukemia in complete remission - a review from the Acute Leukemia Working Party of the EBMT. |
| Q34770016 | Reduced-intensity and myeloablative conditioning allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and myelodysplastic syndrome: a meta-analysis and systematic review |
| Q38366632 | Reduced-intensity conditioned allogeneic SCT in adults with AML. |
| Q35583434 | Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide |
| Q89297777 | The impact of individual comorbidities on non-relapse mortality following allogeneic hematopoietic stem cell transplantation |
| Q87111898 | To RIC or not to RIC: that is the question |
| Q54570201 | Validation of a new integrated prognostic score to predict non-relapse mortality in patients undergoing reduced-intensity conditioning allogeneic hematopoietic cell transplantation. |
| Q40343240 | Validation of the acute leukemia-EBMT score for prediction of mortality following allogeneic stem cell transplantation in a multi-center GITMO cohort |
Search more.